PMID- 24409198
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140110
LR  - 20211021
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 7
IP  - 1
DP  - 2014 Jan
TI  - Prophylactic antiepileptic treatment reduces seizure frequency in 
      natalizumab-associated progressive multifocal leukoencephalopathy.
PG  - 3-6
LID - 10.1177/1756285613503515 [doi]
AB  - OBJECTIVE: Little is known about seizures in natalizumab-associated progressive 
      multifocal leukoencephalopathy (NAT-PML). METHODS: A review of clinical records 
      of 15 NAT-PML patients with multiple sclerosis (MS) treated at a German 
      university hospital. RESULTS: Some 53% (8/15) of our patients developed seizures 
      with often multiple semiologies (seven grand mal, three simple partial motor and 
      two psychomotor seizures). Series of seizures or status epilepticus occurred in 
      seven of these eight. Seizure onset was on average 61 days after onset of NAT-PML 
      and was associated with immune reconstitution inflammatory syndrome (IRIS) in 
      five of eight patients. After having observed severe seizures during NAT-PML in 
      seven of our first nine patients, we started preventive antiepileptic treatment 
      (PAT) with levetiracetam (1000-1750 mg/day). Patient subgroups analyzed for 
      seizures and PAT did not differ in baseline characteristics. Only one of six 
      patients, who received PAT, had a seizure compared with seven of nine patients 
      without PAT (2-tailed Fisher's exact test, p = 0.04). CONCLUSIONS: Although the 
      small sample size and retrospective nature of the study are limitations, we 
      propose to treat NAT-PML patients with PAT early after diagnosis, as seizures 
      seem to be common and severe in NAT-PML.
FAU - Hoepner, Robert
AU  - Hoepner R
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Gudrunstr. 
      56; 44719 Bochum; Germany.
FAU - Dahlhaus, Stefanie
AU  - Dahlhaus S
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Kollar, Susanne
AU  - Kollar S
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Zurawski, Barbara
AU  - Zurawski B
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Chan, Andrew
AU  - Chan A
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Kleiter, Ingo
AU  - Kleiter I
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Gold, Ralf
AU  - Gold R
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
FAU - Hellwig, Kerstin
AU  - Hellwig K
AD  - Department of Neurology, Ruhr University Bochum, St Josef-Hospital, Germany.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC3886383
OTO - NOTNLM
OT  - natalizumab
OT  - preventive antiepileptic treatment
OT  - progressive multifocal leukoence-phalopathy
OT  - seizures
COIS- Conflict of interest statement: A.C. receives financial gratification from Bayer, 
      Biogen-Idec, MerckSerono, Sanofi-Aventis and Teva, and research support from the 
      German Ministry for Education and Research, Bayer, Biogen Idec, MerckSerono and 
      Novartis. I.K. receives financial support from Bayer, Biogen Idec, MerckSerono 
      and Novartis, and research support from Bayer, Novartis Pharma and Biogen Idec. 
      R.G. receives financial support from Biogen Idec, Baxter, Bayer, Chugai 
      Pharmaceuticals, MerckSerono, Novartis, Roche, Sanofi-Aventis, Talecris and TEVA, 
      and research support from Biogen-Idec, Genzyme, MerckSerono and TEVA. K.H. 
      receives financial support from Bayer, Biogen Idec, MerckSerono, Teva, 
      Sanofi-Aventis and Novartis and research support from the German Research 
      Council.
EDAT- 2014/01/11 06:00
MHDA- 2014/01/11 06:01
PMCR- 2014/01/01
CRDT- 2014/01/11 06:00
PHST- 2014/01/11 06:00 [entrez]
PHST- 2014/01/11 06:00 [pubmed]
PHST- 2014/01/11 06:01 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - 10.1177_1756285613503515 [pii]
AID - 10.1177/1756285613503515 [doi]
PST - ppublish
SO  - Ther Adv Neurol Disord. 2014 Jan;7(1):3-6. doi: 10.1177/1756285613503515.